Please login to the form below

Not currently logged in
Email:
Password:

Yescarta

This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Sales of its Kite-partnered CAR-T cell therapy Yescarta (axicabtagene ciloleucel) climbed to $156m in the quarter, an increase on the $120m it generated for the same period in 2019.

Latest news

More from news
Approximately 12 fully matching, plus 51 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics